| 英文名稱 |
中文名稱 |
CAS號 |
操作 |
| Glimepiride Impurity 11 |
格列美脲雜質(zhì)11 |
|
詳細(xì)
|
| Glimepiride Impurity 13 |
格列美脲雜質(zhì)13 |
|
詳細(xì)
|
| Etoposide Impurity 15 |
依托泊苷雜質(zhì)15 |
|
詳細(xì)
|
| Etoposide Impurity 14 |
依托泊苷雜質(zhì)14 |
|
詳細(xì)
|
| Etoposide Impurity 8 |
依托泊苷雜質(zhì)8 |
|
詳細(xì)
|
| Etoposide Impurity 7 |
依托泊苷雜質(zhì)7 |
|
詳細(xì)
|
| Glimepiride Impurity 16 |
格列美脲雜質(zhì)16 |
|
詳細(xì)
|
| Exemestane Impurity J |
依西美坦雜質(zhì)J |
|
詳細(xì)
|
| Exemestane Impurity H |
依西美坦雜質(zhì)H |
|
詳細(xì)
|
| Febuxostat Impurity 62 |
非布索坦雜質(zhì)62 |
|
詳細(xì)
|
| Dextrorotation lansoprazole Impurity 11 |
右旋蘭索拉唑雜質(zhì)11 |
|
詳細(xì)
|
| Dexmedetomidine Impurity A |
右美托咪定雜質(zhì)A |
|
詳細(xì)
|
| Glimepiride Impurity 12 |
格列美脲雜質(zhì)12 |
|
詳細(xì)
|
| Glimepiride Impurity 14 |
格列美脲雜質(zhì)14 |
|
詳細(xì)
|
| Fludarabine Isome L |
氟達(dá)拉濱異構(gòu)體L |
|
詳細(xì)
|
| Glimepiride Impurity 18 |
格列美脲雜質(zhì)18 |
|
詳細(xì)
|
| Glimepiride Impurity 10 |
格列美脲雜質(zhì)10 |
|
詳細(xì)
|
| Etoposide Impurity 10 |
依托泊苷雜質(zhì)10 |
|
詳細(xì)
|
| Enzalutamide PO |
恩雜魯胺PO |
|
詳細(xì)
|
| Etoposide Hydroxy isomer |
依托泊苷羥基異構(gòu)體 |
|
詳細(xì)
|
| Enzalutamide Open - loop impurity |
恩雜魯胺開環(huán)雜質(zhì) |
|
詳細(xì)
|
| Etoposide Impurity 9 |
依托泊苷雜質(zhì)9 |
|
詳細(xì)
|
| Etoposide Impurity 13 |
依托泊苷雜質(zhì)13 |
|
詳細(xì)
|
| Etoposide Impurity 19 |
依托泊苷雜質(zhì)19 |
|
詳細(xì)
|
| Etoposide Impurity 16 |
依托泊苷雜質(zhì)16 |
|
詳細(xì)
|
| Etoposide Impurity 17 |
依托泊苷雜質(zhì)17 |
|
詳細(xì)
|
| Etoposide Impurity 18 |
依托泊苷雜質(zhì)18 |
|
詳細(xì)
|
| Etoposide Impurity 11 |
依托泊苷雜質(zhì)11 |
|
詳細(xì)
|
| Etoposide Impurity 12 |
依托泊苷雜質(zhì)12 |
|
詳細(xì)
|
| Clozapine N-oxide |
|
34233-69-7 |
詳細(xì)
|
| Dabigatran Impurity 20 |
達(dá)比加群酯雜質(zhì)20 |
|
詳細(xì)
|
| Dabigatran Impurity 21 |
達(dá)比加群酯雜質(zhì)21 |
|
詳細(xì)
|
| Glimepiride Impurity 2 |
格列美脲雜質(zhì)2 |
|
詳細(xì)
|
| Glimepiride Impurity 17 |
格列美脲雜質(zhì)17 |
|
詳細(xì)
|
| Glimepiride Impurity 19 |
格列美脲雜質(zhì)19 |
|
詳細(xì)
|
| Glimepiride Impurity 15 |
格列美脲雜質(zhì)15 |
|
詳細(xì)
|
| Glimepiride Impurity 20 |
格列美脲雜質(zhì)20 |
|
詳細(xì)
|
| Glyburide impurity A |
格列本脲雜質(zhì) A |
|
詳細(xì)
|
| Glimepiride Impurity 1 |
格列美脲雜質(zhì)1 |
|
詳細(xì)
|
| Etoposide Impurity S |
依托泊苷雜質(zhì)S |
|
詳細(xì)
|
| Exemestane Impurity I |
依西美坦雜質(zhì)I |
|
詳細(xì)
|
| Etoposide Impurity Z |
依托泊苷雜質(zhì)Z |
|
詳細(xì)
|
| Fludarabine EP impurity A |
磷酸氟達(dá)拉濱EP雜質(zhì)A |
|
詳細(xì)
|
| Glimepiride Impurity 4 |
格列美脲雜質(zhì)4 |
|
詳細(xì)
|
| Glimepiride Impurity 3 |
格列美脲雜質(zhì)3 |
|
詳細(xì)
|
| Clindamycin phosphate Impurity K |
克林霉素磷酸酯雜質(zhì)K |
|
詳細(xì)
|
| Demiditraz Impurity 5 |
得米地曲雜質(zhì)5 |
944263-08-5 |
詳細(xì)
|
| Dextrorotation lansoprazole-N-oxide |
右旋蘭索拉唑-N-氧化物雜質(zhì) |
|
詳細(xì)
|
| Exemestane Impurity D |
依西美坦雜質(zhì) D |
|
詳細(xì)
|
| Glyburide impurity B |
格列本脲雜質(zhì) B |
|
詳細(xì)
|
| Lansoprazole IMpurity K |
右旋蘭索拉唑雜質(zhì)K |
|
詳細(xì)
|
| Lansoprazole IMpurity L |
右旋蘭索拉唑雜質(zhì)L |
|
詳細(xì)
|
| Lansoprazole IMpurity J |
右旋蘭索拉唑雜質(zhì)J |
|
詳細(xì)
|
| Lansoprazole IMpurity I |
右旋蘭索拉唑雜質(zhì)I |
|
詳細(xì)
|
| Lansoprazole IMpurity M |
右旋蘭索拉唑雜質(zhì)M |
|
詳細(xì)
|
| Etoposide Impurity 6 |
依托泊苷雜質(zhì)6 |
|
詳細(xì)
|
| Fludarabine EP impurity J |
氟達(dá)拉濱EP雜質(zhì)J |
|
詳細(xì)
|
| Doxofylline Impurity A |
多索茶堿雜質(zhì)A |
|
詳細(xì)
|
| Etoposide Impurity B |
依托泊苷雜質(zhì)B |
|
詳細(xì)
|
| Etoposide Impurity 4 |
依托泊苷雜質(zhì)4 |
|
詳細(xì)
|
| Etoposide Impurity 1 |
依托泊苷雜質(zhì)1 |
|
詳細(xì)
|
| Etoposide Impurity D |
依托泊苷雜質(zhì)D |
|
詳細(xì)
|
| Etoposide Impurity C |
依托泊苷雜質(zhì) C |
100007-53-2 |
詳細(xì)
|
| Cycloserine Impurity 1 |
環(huán)絲氨酸雜質(zhì)1 |
339-72-0 |
詳細(xì)
|
| Etoposide Impurity E |
依托泊苷雜質(zhì)E |
|
詳細(xì)
|
| Etoposide Impurity 5 |
依托泊苷雜質(zhì)5 |
|
詳細(xì)
|
| Etoposide Impurity 3 |
依托泊苷雜質(zhì)3 |
|
詳細(xì)
|
| Etoposide Impurity 2 |
依托泊苷雜質(zhì)2 |
|
詳細(xì)
|
| Duloxetine IMpurity 11 |
度洛西汀雜質(zhì)11 |
|
詳細(xì)
|
| Dabigatran carbyne Impurity 28 |
達(dá)比加群酯雜質(zhì)28 |
66315-15-9 |
詳細(xì)
|
| Dabigatran Impurity 19 |
達(dá)比加群酯雜質(zhì)19 |
1900865-84-0 |
詳細(xì)
|
| Dabigatran Etexilate iMpurity 23 |
達(dá)比加群酯雜質(zhì)23 |
|
詳細(xì)
|
| Dabigatran Etexilate iMpurity 24 |
達(dá)比加群酯雜質(zhì)24 |
|
詳細(xì)
|
| Dabigatran Impurity R |
達(dá)比加群酯雜質(zhì)25 |
1643377-48-3 |
詳細(xì)
|
| Dabigatran Impurity 27 |
達(dá)比加群酯雜質(zhì)27 |
1643392-59-9 |
詳細(xì)
|
| Dabigatran Etexilate iMpurity 26 |
達(dá)比加群酯雜質(zhì)26 |
|
詳細(xì)
|
| Dabigatran Impurity 35 |
達(dá)比加群酯雜質(zhì)35 |
58906-62-0 |
詳細(xì)
|
| Exemestane Impurity E |
依西美坦雜質(zhì)E |
152764-24-4 |
詳細(xì)
|
| Exemestane Impurity G |
依西美坦雜質(zhì)G |
152764-31-3 |
詳細(xì)
|
| Fasudil N-Hydroxy Impurity |
法舒地爾N-羥基雜質(zhì) |
1350827-92-7 |
詳細(xì)
|
| Fasudil Dimer |
法舒地爾二聚體 |
1337967-93-7 |
詳細(xì)
|
| Fludarabine EP impurity F |
氟達(dá)拉濱EP雜質(zhì)F |
159002-28-5 |
詳細(xì)
|
| Fludarabine EP impurity D |
氟達(dá)拉濱EP雜質(zhì)D |
700-49-2 |
詳細(xì)
|
| Fludarabine EP impurity I |
氟達(dá)拉濱EP雜質(zhì)I |
7561-54-8 |
詳細(xì)
|
| Fludarabine EP impurity C |
氟達(dá)拉濱EP雜質(zhì)C |
548774-53-4 |
詳細(xì)
|
| Fludarabine EP impurity B |
氟達(dá)拉濱EP雜質(zhì)B |
149297-79-0 |
詳細(xì)
|
| (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl) |
氟達(dá)拉濱EP雜質(zhì)E |
21679-14-1 |
詳細(xì)
|
| ((2R,3S,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl) |
氟達(dá)拉濱EP雜質(zhì)K |
|
詳細(xì)
|
| Clavulanic acid Impurity M |
克拉維酸雜質(zhì)M |
3033-62-3 |
詳細(xì)
|
| Clavulanic acid Impurity L |
克拉維酸雜質(zhì)L |
4013-94-9 |
詳細(xì)
|
| Baricitinib Impurity I |
度洛西汀雜質(zhì)D |
90-15-3 |
詳細(xì)
|
| 116539-60-7;(R)-N-methyl-3-(naphthalen-1-yloxy) |
度洛西汀雜質(zhì)A |
910138-96-4 |
詳細(xì)
|
| (R)-N,N-dimethyl-3-(naphthalen-1-yloxy) |
度洛西汀雜質(zhì)9 |
878757-08-5 |
詳細(xì)
|
| Duloxetine impurity G |
度洛西汀雜質(zhì)G |
321-38-0 |
詳細(xì)
|
| Duloxetine EP impurity F |
度洛西汀雜質(zhì)F |
959392-22-4 |
詳細(xì)
|
| (S)-3-(dimethylamino)-1-(thiophen-3-yl)propan-1-ol |
度洛西汀雜質(zhì)18 |
1384080-56-1 |
詳細(xì)
|
| (R)-3-(methylamino)-1-(thiophen-2-yl)propan-1-ol |
度洛西汀雜質(zhì)14 |
116539-57-2 |
詳細(xì)
|
| Duloxetine IMpurity 19 |
度洛西汀雜質(zhì)19 |
1384080-33-4 |
詳細(xì)
|
| 1-methyl-12-thioxobenzo[4',5']imidazo |
右旋蘭索拉唑雜質(zhì)H |
|
詳細(xì)
|
| 1,3-dimethyl-6,7,9,10-tetrahydro-7,10 |
多索茶堿雜質(zhì)B |
|
詳細(xì)
|